Related Experiment Video
Updated: Jul 7, 2026
09:40
Magnetic Adjustment of Afterload in Engineered Heart Tissues
Published on: May 5, 2020
Promoting physiological hypertrophy in the failing heart
Lynette Pretorius1, Kate L Owen, Garry L Jennings
1Baker Heart Research Institute, and Faculty of Medicine, Nursing and Health Sciences, Department of Medicine (Alfred Hospital), Monash University, Melbourne, Victoria, Australia.
Clinical and Experimental Pharmacology & Physiology
|March 1, 2008
Summary
Heart failure is a growing epidemic. Activating the insulin-like growth factor 1-phosphoinositide-3-kinase pathway to promote physiological hypertrophy may improve cardiac function in failing hearts.
Area of Science:
- Cardiology and Molecular Biology
Background:
- Heart failure prevalence is increasing significantly in Western societies.
- Current research explores novel strategies to enhance cardiac function in failing hearts.
Purpose of the Study:
- To review studies investigating the potential benefits of promoting physiological hypertrophy in the context of heart failure.
- To highlight the role of specific signaling pathways in cardiac growth and function.
Main Methods:
- This mini-review synthesizes findings from existing research studies.
- Focuses on the insulin-like growth factor 1-phosphoinositide-3-kinase pathway as a key regulator.
Main Results:
- The insulin-like growth factor 1-phosphoinositide-3-kinase pathway is a known regulator of physiological hypertrophy.
- Evidence suggests that inducing physiological hypertrophy could be a beneficial therapeutic approach for heart failure.
Conclusions:
- Promoting physiological hypertrophy via pathways like IGF-1/PI3K may offer a promising strategy for treating heart failure.
- Further research into these mechanisms could lead to new cardiac therapies.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...